Insys Therapeutics (INSY) said Friday that recent statements relating to the Arizona Attorney General’s investigation of the company lack context and factual accuracy.
The company said the allegations contained in the AG’s complaint relate to former employees and physicians that are no longer associated with the company and that it will cooperate with the investigation.
“By many estimates, the national opioid crisis began more than a decade and a half ago,” Insys said. “Our product, Subsys, has been available since March 2012. In 2016, Subsys accounted for less than 1,450 prescriptions in the State of Arizona when compared to over 4.7 million opioid prescriptions in the State of Arizona during the same period. In other words, in 2016, Subsys was less than 0.03% of all opioid prescriptions in the State of Arizona,” the company said.